3837biotransformation (metabolism) of drugs
TRANSCRIPT
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
1/31
Biotransformation
(Metabolism) of Drugs
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
2/31
A. General properties
1. Biotransformation is a major mechanism fordrugelimination;
Results of biotransformation:
Production of metabolites that are more polar thanthe parent drug
usually terminates the pharmacologic action of theparent drug
After phase I reactions, similar or different
pharmacologic activity, or toxicologic activity.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
3/31
Results of biotransformation
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
4/31
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
5/31
2. Many drugs undergo
several sequential biotransformation reactions.
Biotransformation is catalyzed by specific enzyme systems
3. Sites of biotransformation:
The liver: the major site
other tissues.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
6/31
4. Biotransformation of drugs can be affected by manyparameters, including:
A. prior administration of the drug in question or of other drugs
B. diet
C. hormonal status
D. genetics
E. disease (e.g., decreased in cardiac and pulmonary disease)F. age and developmental status
G. liver function
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
7/31
5. Possible consequences of biotransformationinclude the production of:
inactive metabolites (most common)
metabolites with increased or decreased potencies
metabolites with qualitatively differentpharmacologic actions
toxic metabolites
active metabolites from inactive prodrugs.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
8/31
Metabolites are often more polarthan the parent
compounds.
This increased polarity may lead to:
a more rapid rate of clearance because of possible
secretion by acid or base carriers in the kidney
it may lead to decreased tubular reabsorption.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
9/31
B. Classification of biotransformation reactions
1. Reactions that involve enzyme-catalyzedbiotransformation of the drug without any conjugations.
Phase I reactions include:
oxidations reductions
hydrolysis reactions
they introduce a functional group (e.g., -OH) that serves
as the active center for sequential conjugation in aphase II reaction.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
10/31
2. Reactions that include conjugation reactions, which
involve the enzyme-catalyzed combination of a drug (or
drug metabolite) with an endogenous substance.
Phase II reactions require:
a functional groupanactive centeras the site of
conjugation with the endogenous substance.
energyindirectly for the synthesis of activated
carriers, the form of the endogenous substance used
in the conjugation reaction (e.g., UDP-glucuronate).
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
11/31
Drug metabolism reactions :
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
12/31
C. Enzymes catalyzing phase I biotransformation
reactions
Enzymes catalyzing phase I biotransformationreactions include:
cytochrome P-450
aldehyde and alcohol dehydrogenase
deaminases
esterases
amidases
epoxide hydratases
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
13/31
Enzymes catalyzing phase II biotransformation
reactions include:
glucuronyl transferase (glucuronide conjugation)
sulfotransferase (sulfate conjugation) transacylases (amino acid conjugation)
acetylases
ethylases
methylases
glutathione transferase.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
14/31
Location of these enzymes:
numerous tissues
some are present in plasma.
Subcellular locations include:
cytosol
mitochondria
endoplasmic reticulum
Only those enzymes located in the endoplasmic
reticulum are inducible by drugs
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
15/31
1. Cytochrome P-450 monooxygenase
(mixed function oxidase)
a. General features
A large number of families (at least 18 in mammals) ofcytochrome P-450 (abbreviated CYP) enzymes
exists each member of which catalyzes the biotransformation
of a unique spectrum of drugs
some overlap in the substrate specificities.
This enzyme system is the one most frequentlyinvolved in phase I reactions.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
16/31
The cytochrome P-450 families are referred to usingan arabic numeral, e.g., CYP1, CYP2, etc.
Each family has a numberof subfamilies denoted by
an upper case letter, e.g., CYP2A, CYP2B, etc.
The individual enzymes within each subfamily aredenoted by another arabic numeral, e.g., CYP3A1,CYP3A2, etc.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
17/31
Cytochrome P-450 catalyzes numerous reactions,including:
aromatic and aliphatic hydroxylations
dealkylations at nitrogen, sulfur, and oxygen atoms heteroatom oxidations at nitrogen and sulfur atoms
reductions at nitrogen atoms
ester and amide hydrolysis
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
18/31
The CYP3A subfamily is:
responsible for up to half of the total cytochrome P-450 in the liver
accounts for approximately 50% of the metabolism ofclinically important drugs.
CYP3A4is a particularly abundant enzyme.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
19/31
representative P450 isozymes.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
20/31
b. Localization
The primary location of cytochrome P-450 is the liver,
Other tissues, including: the adrenals
ovaries and testis
tissues involved in steroidogenesis and steroid metabolism.
The enzyme's subcellular location is the endoplasmicreticulum.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
21/31
c. Mechanism of reaction
1. In the overall reaction:
the drug is oxidized
oxygen is reduced to water.
Reducing equivalents are provided by nicotinamide
adenine dinucleotide phosphate (NADPH), and
generation of this cofactor is coupled to cytochrome
P-450 reductase.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
22/31
d. Genetic polymorphisms
Genetic polymorphism of several clinically importantcytochrome P-450s, particularly CYP2Cand CYP2D,
is a source of variable metabolism in humans,including differences among racial and ethnic groups.
These enzymes have substantially different properties
(V
max orK
m).
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
23/31
e. Induction of drug metabolism :
Enzyme synthesis initiated within 24 h of exposure,increasing over 35 days
Effect decreases over 13 weeks after inducing agentis discontinued
Environmental Factors:Cigarette smoking
eating BBQ meat
cruciferous veggies (plants in the mustard family whichincludes the cabbage, radish, broccoli, and many weeds.)
high protein diet
Ethanol
exposure to insecticides (DDT, Lindane) & PCBs
(polychlorinated biphenyls)
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
24/31
Other drugs: Barbiturates
Phenytoin
Carbamazepine Rifampicin
dexamethasone
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
25/31
f. Inhibition
Rapid onset within 1 day
Competitive or noncompetitive (clinically more likely)inhibition of P-450 enzyme activity can result in thereduced metabolism of other drugs or endogenoussubstrates such as testosterone.
Inhibition can be caused by a number ofcommonlyused drugs, including:
Cimetidine fluconazole
Fluoxetine
Erythromycin
grapefruit juice.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
26/31
Glucuronyl Transferse
1. General features
Glucuronyl transferase is a set of enzymes withunique but overlapping specificities that are involvedin phase II reactions.
It catalyzes the conjugation of glucuronic acid to avariety of active centers, including: -OH
-COOH -SH
-NH2
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
27/31
2. Mechanism of reaction UDP-glucuronic acid, the active glucuronide donor, is formed
from UTP and glucose 1-phosphate.
Glucuronyl transferase then catalyzes the conjugation to theactive center of the drug.
3. Location and induction Glucuronyl transferase is located in the endoplasmic
reticulum.
It is the only phase II reaction that is inducible by drugs and isa possible site of drug interactions.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
28/31
Metabolism of phenytoin :
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
29/31
Inhibitors of intestinal P glycoprotein:
P-glycoprotein (P-gp) has been identified as animportant modulator of intestinal drug transport andusually functions to expel drugs from the intestinalmucosa into the lumen.
Drugs that inhibit intestinal P-gp mimic drugmetabolism inhibitors by increasing bioavailability andmay result in toxic plasma concentrations of drugsgiven at normally nontoxic dosage.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
30/31
P-gp inhibitors include:
Verapamil
grapefruit juice
Important drugs that are normally expelled by P-gp (andwhich are therefore potentially more toxic when givenwith a P-gp inhibitor) include digoxin, cyclosporine, andsaquinavir.
-
7/27/2019 3837Biotransformation (Metabolism) of Drugs
31/31
Metabolism of acetaminophen to harmless conjugates or to toxic metabolites.
nontoxic phase II conjugatesnontoxic phase II conjugates
toxic
phase I ReactionAc* production increases:
1. Depletion of hepatic stores
of sulfate, glucuronide, and
glutathione
2. Overwhelm phase II rxns3. Induction of phase I enzymes